Optimal oral antiplatelet therapy for vascular diseaseBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7482.0-e (Published 06 January 2005) Cite this as: BMJ 2005;330:0-e
Question Which antiplatelet agents, used alone or in combination, are effective in preventing recurrent vascular events?
Synopsis Aspirin prevents recurrent vascular events in a wide range of high risk patients, but it is unknown if other antiplatelet agents, such as clopidogrel or dipyridamole, alone or in combination with aspirin, are more effective. The investigators rigorously searched multiple databases including Medline, the Cochrane clinical trials registry, and reference lists of trials, review articles, and scientific statements and guidelines of official societies. They included randomised trials comparing an antiplatelet regimen to either placebo or another antiplatelet regimen assessing outcomes for at least …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial